Hoechst Marion Roussel and Rhône-Poulenc Rorer announced they plan to boost their combined sales force to 4,000 reps.
In an update to the recent announcement that they plan to merge, Hoechst Marion Roussel, Germany, and Rhône-Poulenc Rorer, France, announced they plan to boost their combined sales force to 4,000 reps.
Currently, their combined sales forces total 3,400 reps. While that number might have seemed large two years ago, it places the sales force of the future consolidated company, Aventis Pharma, in sixth place in the United States.
"These substantial marketing resources will enable Aventis Pharma to leverage fast-growing products," the companies said in a formal statement.
Sales reps will be responsible for promoting current products, such as Hoechst Marion Roussel's antiallergy medicine Allegra and Rhône-Poulenc Rorer's low-molecular weight heparin Lovenox and anticancer drug Taxotere.
In the future, pending FDA approval, Aventis reps could also be responsible for promoting the anti-osteoporosis medicine Actonel, the rheumatoid arthritis medicine Arava, the anti-infective Synercid and drugs for cardiovascular diseases and psychoses.
Presumably, the increase in the sales force will take place upon completion of phase one of a two-stage merger.
In phase one, the two companies will form a 50/50 joint venture of pharmaceutical and agricultural activities. In phase two, which should take place in three years, the parent companies will fully merge, bringing their shareholdings together.
Phase one of the merger, which must receive European regulatory approval, is scheduled for mid-1999. PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.